[Haemorrhagic complications following ibrutinib intake after dermatological surgery].
DISCUSSION: Ibrutinib is a tyrosine kinase inhibitor whose mechanism of action plays a role in platelet adhesion. It is known to cause haemorrhaging, either spontaneously or following invasive procedures, especially at the beginning of treatment. In the case of low-risk haemorrhagic procedures in which bleeding may be controlled by mechanical haemostasis, ibrutinib should be discontinued 3 days before and after surgery. In the event of recent initiation of ibrutinib and in the absence of urgent dermatological management, it is preferable to schedule any surgical procedures 3 months after the start of ibrutinib.
PMID: 32917401 [PubMed - as supplied by publisher]
Source: Annales de Dermatologie et de Cenereologie - Category: Dermatology Authors: Lebas D, Preta LH, Leguern A, Modiano P, Wiart T Tags: Ann Dermatol Venereol Source Type: research
More News: Bleeding | Cancer & Oncology | Carcinoma | Chronic Leukemia | Chronic Lymphocytic Leukemia | Dermatology | Leukemia | Oral Cancer | Skin